JP2009521496A - ＴＧＦ−β結合組成物 - Google Patents

ＴＧＦ−β結合組成物 Download PDF

Info

Publication number
JP2009521496A
JP2009521496A JP2008547744A JP2008547744A JP2009521496A JP 2009521496 A JP2009521496 A JP 2009521496A JP 2008547744 A JP2008547744 A JP 2008547744A JP 2008547744 A JP2008547744 A JP 2008547744A JP 2009521496 A JP2009521496 A JP 2009521496A
Authority
JP
Japan
Prior art keywords
seq
tgf
antibody
antibodies
human tgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2008547744A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009521496A5 (https=
Inventor
ブライアン・エドワード・ジョーンズ
ジェイムズ・ディ・パンクック
スコット・ウィリアム・ローリンソン
Original Assignee
イーライ リリー アンド カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イーライ リリー アンド カンパニー filed Critical イーライ リリー アンド カンパニー
Publication of JP2009521496A publication Critical patent/JP2009521496A/ja
Publication of JP2009521496A5 publication Critical patent/JP2009521496A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2008547744A 2005-12-23 2006-12-20 ＴＧＦ−β結合組成物 Ceased JP2009521496A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75395605P 2005-12-23 2005-12-23
PCT/US2006/062397 WO2007076391A1 (en) 2005-12-23 2006-12-20 Tgf-beta binding compositions

Publications (2)

Publication Number Publication Date
JP2009521496A true JP2009521496A (ja) 2009-06-04
JP2009521496A5 JP2009521496A5 (https=) 2010-02-12

Family

ID=37898733

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008547744A Ceased JP2009521496A (ja) 2005-12-23 2006-12-20 ＴＧＦ−β結合組成物

Country Status (10)

Country Link
US (3) US7494651B2 (https=)
EP (1) EP1966243B1 (https=)
JP (1) JP2009521496A (https=)
CN (1) CN101346394B (https=)
AT (1) ATE545657T1 (https=)
AU (1) AU2006330542B2 (https=)
BR (1) BRPI0620240A2 (https=)
CA (1) CA2632799A1 (https=)
ES (1) ES2379194T3 (https=)
WO (1) WO2007076391A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518064A (ja) * 2011-06-03 2014-07-28 ゾーマ テクノロジー リミテッド ＴＧＦ−βに特異的な抗体
KR20150132262A (ko) * 2013-03-20 2015-11-25 젠자임 코포레이션 불완전 골형성증의 치료 방법
WO2016024628A1 (ja) * 2014-08-14 2016-02-18 学校法人東京医科大学 樹状細胞の抗癌免疫賦活能の促進方法およびその用途
JP2025028981A (ja) * 2017-01-20 2025-03-05 ジェンザイム・コーポレーション 骨標的抗体

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1961003B (zh) * 2004-03-31 2013-03-27 健泰科生物技术公司 人源化抗TGF-β抗体
JP2009521496A (ja) * 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物
US8350006B2 (en) * 2008-10-24 2013-01-08 Mead Johnson Nutrition Company Methods for determining the bioactivity of TGF-β in a composition
EP2382321A4 (en) * 2009-01-08 2012-12-19 Bio Rad Laboratories METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY OF NUCLEIC ACID AMPLIFICATION REACTIONS
US20120294868A1 (en) * 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
US10259626B2 (en) 2012-03-08 2019-04-16 Selig Sealing Products, Inc. Container sealing member with protected security component and removal tab
WO2013134365A1 (en) 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
EP3244926B8 (en) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
TWI726870B (zh) 2015-03-04 2021-05-11 美商健臻公司 具有高親和性、結合性及專一性之結合轉形生長因子-β１的ｓｃＦｖ-Ｆｃ二聚體
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體
EP3770171A1 (en) 2015-04-03 2021-01-27 XOMA Technology Ltd. Treatment of cancer using inhibitors of tgf-beta and pd-1
US10723793B2 (en) 2015-06-12 2020-07-28 Ludwig Institute For Cancer Research, Ltd. TGF-β3 specific antibodies and methods and uses thereof
WO2017201036A1 (en) 2016-05-17 2017-11-23 Genentech, Inc. Stromal gene signatures for diagnosis and use in immunotherapy
GB201610044D0 (en) 2016-06-08 2016-07-20 Ucb Biopharma Sprl Antibodies
CN109071656B (zh) 2017-01-05 2021-05-18 璟尚生物制药公司 检查点调节物拮抗剂
ES2984919T3 (es) 2017-11-06 2024-10-31 Hoffmann La Roche Procedimientos diagnósticos y terapéuticos para el cáncer
CN112739717B (zh) 2018-06-29 2025-02-11 璟尚生物制药公司 三特异性拮抗剂
WO2020095113A1 (en) 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
CN113613726B (zh) 2018-11-05 2025-07-15 路德维格癌症研究所有限公司 人源化和变体TGF-β3特异性抗体及其方法和用途
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
CA3152371A1 (en) 2019-08-01 2021-02-04 Vaccinex, Inc. Combined inhibition of semaphorin-4d and tgf.beta. and compositions therefor
US11801304B2 (en) 2020-02-19 2023-10-31 Nammi Therapeutics, Inc. Formulated and/or co-formulated liposome compositions containing TFGB antagonist prodrugs useful in the treatment of cancer and methods thereof
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
US20220119513A1 (en) * 2020-06-08 2022-04-21 Zoetis Services Llc Anti-tgfb antibodies and therapeutic uses thereof
US20240002479A1 (en) * 2020-11-23 2024-01-04 The Regents Of The University Of Michigan Single-chain antibody against flavivirus ns1 protein
WO2022115611A1 (en) 2020-11-25 2022-06-02 Catamaran Bio, Inc. Cellular therapeutics engineered with signal modulators and methods of use thereof
CN112940119B (zh) * 2021-04-26 2022-05-20 北京芳渟阳生生物科技有限公司 一种单克隆抗体及其与间充质干细胞外泌体的联合应用
CN115707716A (zh) * 2021-08-18 2023-02-21 丹生医药技术(上海)有限公司 一种TGF-β/VEGF双功能抗体融合蛋白
WO2023080900A1 (en) 2021-11-05 2023-05-11 Genentech, Inc. Methods and compositions for classifying and treating kidney cancer
US20250282874A1 (en) 2022-05-17 2025-09-11 Suzhou Transcenta Therapeutics Co., Ltd. Bifunctional protein, and preparation thereof and use thereof
WO2024077166A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating lung cancer
WO2024077095A1 (en) 2022-10-05 2024-04-11 Genentech, Inc. Methods and compositions for classifying and treating bladder cancer
WO2024149237A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
JP2009521496A (ja) * 2005-12-23 2009-06-04 イーライ リリー アンド カンパニー ＴＧＦ−β結合組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005010049A2 (en) * 2003-07-09 2005-02-03 Eli Lilly And Company Tgf-beta1 ligands
WO2005097832A2 (en) * 2004-03-31 2005-10-20 Genentech, Inc. Humanized anti-tgf-beta antibodies

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021112204A (ja) * 2011-06-03 2021-08-05 ゾーマ テクノロジー リミテッド ＴＧＦ−βに特異的な抗体
JP2020014464A (ja) * 2011-06-03 2020-01-30 ゾーマ テクノロジー リミテッド ＴＧＦ−βに特異的な抗体
KR102577578B1 (ko) 2011-06-03 2023-09-11 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
JP7179903B2 (ja) 2011-06-03 2022-11-29 ゾーマ テクノロジー リミテッド ＴＧＦ－βに特異的な抗体
JP2018172412A (ja) * 2011-06-03 2018-11-08 ゾーマ テクノロジー リミテッド ＴＧＦ−βに特異的な抗体
KR20220063297A (ko) * 2011-06-03 2022-05-17 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
JP2014518064A (ja) * 2011-06-03 2014-07-28 ゾーマ テクノロジー リミテッド ＴＧＦ−βに特異的な抗体
JP7016113B2 (ja) 2013-03-20 2022-02-04 ジェンザイム・コーポレーション 骨形成不全症の処置方法
KR102257138B1 (ko) 2013-03-20 2021-05-26 젠자임 코포레이션 불완전 골형성증의 치료 방법
KR20150132262A (ko) * 2013-03-20 2015-11-25 젠자임 코포레이션 불완전 골형성증의 치료 방법
JP2020109110A (ja) * 2013-03-20 2020-07-16 ジェンザイム・コーポレーション 骨形成不全症の処置方法
JP2019089826A (ja) * 2013-03-20 2019-06-13 ジェンザイム・コーポレーション 骨形成不全症の処置方法
JP2016519093A (ja) * 2013-03-20 2016-06-30 ジェンザイム・コーポレーション 骨形成不全症の処置方法
WO2016024628A1 (ja) * 2014-08-14 2016-02-18 学校法人東京医科大学 樹状細胞の抗癌免疫賦活能の促進方法およびその用途
JP2025028981A (ja) * 2017-01-20 2025-03-05 ジェンザイム・コーポレーション 骨標的抗体

Also Published As

Publication number Publication date
AU2006330542A1 (en) 2007-07-05
US7927593B2 (en) 2011-04-19
WO2007076391A1 (en) 2007-07-05
EP1966243A1 (en) 2008-09-10
CN101346394B (zh) 2012-07-25
US20090155285A1 (en) 2009-06-18
WO2007076391A9 (en) 2008-08-28
AU2006330542B2 (en) 2012-05-24
US7494651B2 (en) 2009-02-24
US20080292638A1 (en) 2008-11-27
US20100136021A1 (en) 2010-06-03
ATE545657T1 (de) 2012-03-15
CA2632799A1 (en) 2007-07-05
CN101346394A (zh) 2009-01-14
EP1966243B1 (en) 2012-02-15
ES2379194T3 (es) 2012-04-23
BRPI0620240A2 (pt) 2011-11-08

Similar Documents

Publication Publication Date Title
US7927593B2 (en) TGF-beta binding antibodies
CN110606891B (zh) 一种针对人cldn18.2的抗体分子，抗原结合片段及其医药用途
CN114502591B (zh) 靶向bcma的抗体、双特异性抗体及其用途
TWI417106B (zh) 巨噬細胞-刺激蛋白質受體（ｒｏｎ）之抑制及其治療方法
CN105829345B (zh) 结合egfr和met的多功能抗体
CN107001471A (zh) 抗met抗体和组合物
US20090246205A1 (en) Inhibition of macrophage-stimulating protein receptor (ron)
US9695241B2 (en) Ang2 antibodies
CA2986066A1 (en) Multi-specific binding proteins
JP6592600B2 (ja) 抗ｃｇｒｐ／抗ｉｌ−２３二重特異性抗体及びその使用
AU2021307516B2 (en) Anti-CLDN-18.2 antibody and use thereof
US20240400711A1 (en) Cd38 monoclonal antibody and application thereof
CA3230246A1 (en) Bispecific antibody and use thereof
TWI858383B (zh) 一種ｃｄｃ平臺抗體
US20240301051A1 (en) Anti-cldn6 antibodies and methods of use
US20240301061A1 (en) Anti-cldn6 and anti-cd3 multispecific antibodies and methods of use
US20240301062A1 (en) Anti-cd3 multispecific antibodies and methods of use
MX2008008137A (en) Tgf-beta binding compositions
WO2016040767A2 (en) Chrdl-1 epitopes and antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20091216

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20091216

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20091216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120306

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120606

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120814

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20121225